2β,3β,14α-Trihydroxy-6,20-dioxo-5β-pregnen-7 | 10162-99-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 2β,3β,14α-Trihydroxy-6,20-dioxo-5β-pregnen-7
• 英文别名: 2β.3β.14α-Trihydroxy-5β-pregn-7-en-6.20-dion；(2S,3R,5R,10R,13R,14S,17S)-17-acetyl-2,3,14-trihydroxy-10,13-dimethyl-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-6-one
• CAS: 10162-99-9；144405-75-4
• 化学式: C₂₁H₃₀O₅
• 分子量: 362.466
• InChiKey: VNLQNGYIXVTQRR-ZRYTYNJLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  26
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  94.8
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• Chemical compounds and use thereof for improving muscular quality
  申请人：BIOPHYTIS

  公开号：US10316056B2

  公开（公告）日：2019-06-11

  Chemical compounds and the therapeutic use thereof, in particular for improving muscular quality in mammals. More particularly, a method of improving muscular quality in sarcopenic mammals and treating and/or preventing sarcopenia using the chemical compounds and, in particular, sarcopenic obesity and the associated complications and/or pathologies thereof, such as loss of strength, muscle mass, performance and of physical and movement capacity. Also, a method of improving muscle quality in obese mammals and treating and/or preventing of obesity and associated complications and/or pathologies, advantageously type 2 diabetes and metabolic syndrome, using the chemical compounds.

  化合物及其治疗用途，特别是用于改善哺乳动物的肌肉质量。更具体地说，一种改善肌肉疏松哺乳动物肌肉质量的方法，以及使用该化合物治疗和/或预防肌肉疏松症的方法，特别是肌肉疏松性肥胖症及其相关并发症和/或病症，如力量、肌肉质量、表现和体能及运动能力的丧失。此外，还包括一种改善肥胖哺乳动物肌肉质量的方法，以及使用该化合物治疗和/或预防肥胖症及相关并发症和/或病症，尤其是 2 型糖尿病和代谢综合征。
• COMPOSÉS CHIMIQUES ET LEUR UTILISATION POUR L'AMÉLIORATION DE LA QUALITÉ MUSCULAIRE
  申请人：Biophytis

  公开号：EP3145942B1

  公开（公告）日：2019-04-03
• CHEMICAL COMPOUNDS AND USE THEREOF FOR IMPROVING MUSCULAR QUALITY
  申请人：BIOPHYTIS

  公开号：US20170226151A1

  公开（公告）日：2017-08-10

  Chemical compounds and the therapeutic use thereof, in particular for improving muscular quality in mammals. More particularly, a method of improving muscular quality in sarcopenic mammals and treating and/or preventing sarcopenia using the chemical compounds and, in particular, sarcopenic obesity and the associated complications and/or pathologies thereof, such as loss of strength, muscle mass, performance and of physical and movement capacity. Also, a method of improving muscle quality in obese mammals and treating and/or preventing of obesity and associated complications and/or pathologies, advantageously type 2 diabetes and metabolic syndrome, using the chemical compounds.
• USE OF 20-HYDROXYECDYSONE AND THE DERIVATIVES THEREOF IN THE TREATMENT OF MYOPATHIES
  申请人：BIOPHYTIS

  公开号：US20200179407A1

  公开（公告）日：2020-06-11

  The invention relates to 20-hydroxyecdysone and the derivatives thereof, for use in the treatment of genetic myopathies.
• US9938315B2
  申请人：——

  公开号：US9938315B2

  公开（公告）日：2018-04-10